A previous study showed that bevacizumab combined with afatinib induced a positive conversion of T790M mutation in previously EGFR-TKI-resistant NSCLC patients without secondary T790M mutation [35]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.